UPDATE: Benchmark Company Terminates Coverage on BioClinica Following Acquisition by JLL Partners

In a report published Monday, Benchmark Company analyst Raymond Myers terminated the firm's coverage of BioClinica

. In the report, Myers noted, “BioClinica announced it has completed its previously disclosed agreement with the private equity firm, JLL Partners, to acquire BioClinica for $7.25 per share. BIOC shares are no longer publicly listed. At the time of announcement this reflected 1.6x our forecast 2012 revenue of $77.4 million and was a 23% premium to the prior 90-day trading average. Our prior forecasts and rating should no longer be relied upon; our prior Hold rating reflected the limited upside to the agreed $7.25 transaction price.” BioClinica closed on Friday at $7.25.